OPGN Stock Price Increases Over 40% Pre-Market: Why It Happened

Investors appear to be responding to the company announcing the release of a new peer-reviewed publication that demonstrates that the Unyvero Hospitalized Pneumonia (HPN) panel is a reliable and rapid diagnostic test with high negative predictive value for the detection of bacterial pathogens directly from native lower respiratory tract samples, allowing identification of bacterial co-infections in hospitalized patients with COVID-19 pneumonia in just five hours.

The overall positive percent agreement (PPA, sensitivity) and negative percent agreement (NPA, specificity) with culture for detection and identification of bacteria that grow in routine cultures were 95.1% and 98.3%, respectively – which is consistent with the performance of the Unyvero Lower Respiratory Panels (LRT and LRT BAL) that have been published recently by Mackenzie E. Collins and colleagues and Matthias Klein et al.

The study demonstrated several advantages of the Unyvero HPN panel, including higher diagnostic yield compared to SoC culture alone – which enabled the identification of additional clinically important pathogens like Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Haemophilus influenzae, Stenotrophomonas maltophilia, among several others in 25% of cases that were missed by microbiological methods.

And it is most likely possible that the bacterial super-infections among COVID-19 patients admitted to critical care units are due to the longer durations of stay in the ICU and mechanical ventilation, rather than the viral infection itself, but nonetheless this requires diligent microbiological testing because the signs and symptoms can be similar and confounding.”

The Unyvero Hospitalized Pneumonia (HPN) panel detects 21 clinically relevant pathogens and 17 antibiotic resistance markers in less than 5 hours directly from native specimens with only around 2 minutes of hands-on time, compared to routine bacterial cultures that can take up to several days for confirmatory pathogen identification and antimicrobial susceptibility testing results.

Unyvero HPN and LRT BAL are the only syndromic multiplex PCR panels for lower respiratory tract infections that also include Pneumocystis jirovecii, a causative agent of Pneumocystis pneumonia (PCP) and a key fungal pathogen often found in immunocompromised patients that can be difficult to diagnose.

Powered by Blogger.